HAEMONETICS CORP (HAE) Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Haemonetics Corporation NYSE:HAE Healthcare · Medical - Instruments & Supplies
Mkt Cap $5.44B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
globenewswire.com • 11d ago Press Release
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics received FDA approval for the PerQseal Elite vascular closure system for large-bore arterial procedures, expanding its U.S. large-bore closure portfolio for structural heart and endovascular use.
The fully bioabsorbable patch seals arteriotomies up to 26F, with ELITE study data showing 0% VARC-3 major complications and mean time to hemostasis under one minute; PerQseal Elite won CE Mark approval in Europe in 2025.
The device came with Haemonetics' January 2026 acquisition of Vivasure Medical, and clinical data will be presented at TCT at the end of October — a revenue-growth option within the Interventional Technologies segment rather than a company-defining approval.
• 13d ago AI analysis › Press Release
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
globenewswire.com • 24d ago Press Release
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
globenewswire.com • 27d ago Press Release
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics (NYSE: HAE) announced it will publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
A conference call with investors and analysts will follow at 8:00 am ET the same day, with a live webcast available on the company's investor relations website.
The release is a scheduling notice containing no financial results or guidance.
• 1mo ago AI analysis › Press Release ⚠ 2
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Holdings (Nasdaq: OBIO) received a $6.1 million milestone payment from Haemonetics on September 14, 2026 — the first milestone payment in connection with the previously announced acquisition of Vivasure Medical, which Haemonetics completed on January 9, 2026.
Combined with the roughly $5 million upfront payment received in January, Orchestra BioMed has now collected approximately $11 million from the transaction, completing the amount previously disclosed as expected during 2026, and remains eligible for up to about $10 million more through revenue earnouts for total potential proceeds of up to $21 million.
For Haemonetics (NYSE: HAE), the filer, this is a routine, pre-disclosed contractual payment on an already-closed deal with no change to its operating outlook; the cash is far more meaningful to Orchestra BioMed as it funds pivotal trials of AVIM Therapy and Virtue SAB.
• 1mo ago AI analysis › Press Release
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
globenewswire.com • 1mo ago Press Release
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
globenewswire.com • 2mo ago Press Release
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Haemonetics Corporation announced that its first quarter fiscal 2027 financial results are now available on the company's Investor Relations website. The quarter ended on June 27, 2026.
Management will host a conference call and webcast at 8:00 a.m. ET on August 6, 2026 to discuss the results with investors and analysts.
A replay of the event will be accessible starting at 11:00 a.m. ET on the same day and will remain available for one year.
• 2mo ago AI analysis › Press Release ⚠ 2
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
Haemonetics announced publication of a retrospective study at Emory University involving 1,623 patients, demonstrating the safety and efficacy of the VASCADE MVP XL system in large-bore venous procedures.
Results showed a 92.5% same-day discharge rate with median hemostasis of 2 minutes and a 1.2% vascular complication rate, supporting the system's value in electrophysiology workflows.
The system is compatible with market-leading PFA and LAAC devices from Abbott, Boston Scientific, and Medtronic, following expanded FDA labeling in March 2026.
• 2mo ago AI analysis › Press Release
Martin Madaus Elected to Haemonetics Board of Directors
Martin Madaus has been elected to the Haemonetics Board of Directors, effective July 24, 2026.
Dr. Madaus brings over 30 years of leadership experience in diagnostics and life sciences, currently serving as a Senior Operating Executive at The Carlyle Group, and previously as CEO of Ortho Clinical Diagnostics and Millipore Corporation.
Chair Ellen Zane stated that his track record of operational excellence and creating shareholder value will be invaluable as Haemonetics executes its strategy to expand its leadership in the medical technology market.
• 3mo ago AI analysis › Press Release
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Haemonetics announced it will release its first quarter fiscal year 2027 financial results before market open on August 6, 2026.
The company plans to host a conference call at 8:00 am ET on the same day to discuss the quarterly performance.
Haemonetics specializes in medical technology, focusing on apheresis, blood management, and interventional technologies.
• 3mo ago AI analysis › Press Release
Haemonetics Updates Financial Reporting Segments
Haemonetics is restructuring its financial reporting from three segments to two, combining Plasma and Blood Center into 'Apheresis' and renaming Hospital to 'MedSurg'.
The new structure aligns external reporting with internal management practices and will take effect with Q1 FY2027 results.
The company provided recast historical data for comparability but clarified this is not a guidance update; any guidance changes will be addressed on the upcoming earnings call.
• 4mo ago AI analysis › Press Release
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics CEO Chris Simon will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
The event will be webcast live and available for replay on the company's Investor Relations website for 90 days.
This is a standard investor relations appearance with no new operational or financial disclosures.
• 4mo ago AI analysis › Press Release
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
globenewswire.com • 5mo ago Press Release
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
prnewswire.com • 5mo ago Press Release
Haemonetics to Present at Bank of America 2026 Healthcare Conference
Haemonetics announced that CEO Chris Simon will participate in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026.
The event will be webcast live and available for replay for one year on the company's Investor Relations website.
No new financial or operational guidance was provided in this release.
• 5mo ago AI analysis › Press Release
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
prnewswire.com • 6mo ago 
